LYEL logo Lyell Immunopharma : LYEL

LYEL

Stock Data

$20.83

Change up

$1.10 (5.58%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Lyell Immunopharma Inc is a pioneering force in the field of cell therapy, focusing on the development of innovative treatments for patients with solid tumors. By leveraging cutting-edge genetic and epigenetic reprogramming technologies, the company aims to create more effective and durable T cell therapies. Its product pipeline includes LYL797 and LYL845, both in Phase 1 clinical trials, and LYL119 in preclinical development, targeting a range of solid tumors with enhanced potency. Based in South San Francisco, California, Lyell Immunopharma also collaborates with notable institutions and companies to advance its research and potential therapies.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.